Immune thrombocytopenic purpura associated with fingolimod

Fingolimod is an oral sphingosine-1-phosphate receptor modulator which causes lymphocyte sequestration in lymph nodes and is approved for relapsing multiple sclerosis. The Therapeutic Goods Administration of Australia is aware of only one case where fingolimod preceded immune thrombocytopenic purpur...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ case reports 2017-09, Vol.2017, p.bcr-2017-220590
Hauptverfasser:	Yuen, Hiu Lam Agnes, Brown, Susan, Chan, Noel, Grigoriadis, George
Format:	Artikel
Sprache:	eng
Schlagworte:	Australasia Blood Platelets - drug effects Case reports Cytomegalovirus Disease Management Drug dosages Female Fingolimod Hydrochloride - administration & dosage Fingolimod Hydrochloride - adverse effects Fingolimod Hydrochloride - therapeutic use Glucocorticoids - therapeutic use Hepatitis HIV Human immunodeficiency virus Humans Immunologic Factors - therapeutic use Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Middle Aged Multiple sclerosis Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Natalizumab - therapeutic use Prednisolone - administration & dosage Prednisolone - therapeutic use Purpura, Thrombocytopenic, Idiopathic - chemically induced Purpura, Thrombocytopenic, Idiopathic - drug therapy Receptors, Fc - therapeutic use Receptors, Lysosphingolipid - agonists Recombinant Fusion Proteins - therapeutic use Thrombopoietin - therapeutic use Treatment Outcome Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions White Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!